{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:18:02Z","timestamp":1779898682524,"version":"3.53.1"},"reference-count":40,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Spanish National Institute of Health, Instituto de Salud Carlos III","award":["PI22-00827"],"award-info":[{"award-number":["PI22-00827"]}]},{"name":"Spanish National Institute of Health, Instituto de Salud Carlos III","award":["IISR-2018-104281"],"award-info":[{"award-number":["IISR-2018-104281"]}]},{"name":"Spanish National Institute of Health, Instituto de Salud Carlos III","award":["IIR-ESP-002248"],"award-info":[{"award-number":["IIR-ESP-002248"]}]},{"name":"Spanish National Institute of Health, Instituto de Salud Carlos III","award":["IN607B-2023\/08"],"award-info":[{"award-number":["IN607B-2023\/08"]}]},{"name":"Spanish National Institute of Health, Instituto de Salud Carlos III","award":["IN606A-2023\/024"],"award-info":[{"award-number":["IN606A-2023\/024"]}]},{"name":"Takeda Pharmaceuticals International AG","award":["PI22-00827"],"award-info":[{"award-number":["PI22-00827"]}]},{"name":"Takeda Pharmaceuticals International AG","award":["IISR-2018-104281"],"award-info":[{"award-number":["IISR-2018-104281"]}]},{"name":"Takeda Pharmaceuticals International AG","award":["IIR-ESP-002248"],"award-info":[{"award-number":["IIR-ESP-002248"]}]},{"name":"Takeda Pharmaceuticals International AG","award":["IN607B-2023\/08"],"award-info":[{"award-number":["IN607B-2023\/08"]}]},{"name":"Takeda Pharmaceuticals International AG","award":["IN606A-2023\/024"],"award-info":[{"award-number":["IN606A-2023\/024"]}]},{"DOI":"10.13039\/501100010769","name":"Galician Agency of Innovation","doi-asserted-by":"publisher","award":["PI22-00827"],"award-info":[{"award-number":["PI22-00827"]}],"id":[{"id":"10.13039\/501100010769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010769","name":"Galician Agency of Innovation","doi-asserted-by":"publisher","award":["IISR-2018-104281"],"award-info":[{"award-number":["IISR-2018-104281"]}],"id":[{"id":"10.13039\/501100010769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010769","name":"Galician Agency of Innovation","doi-asserted-by":"publisher","award":["IIR-ESP-002248"],"award-info":[{"award-number":["IIR-ESP-002248"]}],"id":[{"id":"10.13039\/501100010769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010769","name":"Galician Agency of Innovation","doi-asserted-by":"publisher","award":["IN607B-2023\/08"],"award-info":[{"award-number":["IN607B-2023\/08"]}],"id":[{"id":"10.13039\/501100010769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010769","name":"Galician Agency of Innovation","doi-asserted-by":"publisher","award":["IN606A-2023\/024"],"award-info":[{"award-number":["IN606A-2023\/024"]}],"id":[{"id":"10.13039\/501100010769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Fabry disease is an invalidating multisystemic disorder affecting \u03b1-Galactosidase, a rate-limiting hydrolase dedicated to lipid catabolism. Non-metabolized substrates, such as Globotriaosylceramide and its derivatives trigger the direct or indirect activation of inflammatory events and endothelial dysfunction. In spite of the efficacy demonstrated by enzyme replacement therapy or pharmacological chaperones in delaying disease progression, few studies have analyzed whether these treatments can improve the pro-inflammatory state of FD patients. Therefore, the aim of this work was to assess cytokines and cardiovascular risk-related proteins detectable in plasma from FD patients, whether treated or not with ERT, to evaluate the reliability of these markers in monitoring disease stage and treatment effects. We identified inflammatory and endothelial dysfunction markers (ADAMTS-13, TNF-\u03b1, GDF-15, MIP-1\u03b2, VEGFA, MPO, and MIC-1) that cooperate in a common pathway and are increased in FD patients\u2019 plasma samples. As shown by the assessment of these proteins over time, they can help to evaluate the risk of higher severity in FD, as well as ERT effects. Even though the analyzed proteins cannot be considered as proper biomarkers due to their non-specificity to FD, taken together they can provide a signature of reference molecules with prognostic value for early diagnosis, and evaluation of disease progression and treatment efficacy, using blood samples.<\/jats:p>","DOI":"10.3390\/ijms25116024","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T03:46:49Z","timestamp":1717127209000},"page":"6024","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Inflammatory and Cardiovascular Biomarkers to Monitor Fabry Disease Progression"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3488-9173","authenticated-orcid":false,"given":"Adri\u00e1n","family":"Alonso-N\u00fa\u00f1ez","sequence":"first","affiliation":[{"name":"Rare Diseases & Pediatric Medicine Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, 36312 Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"P\u00e9rez-M\u00e1rquez","sequence":"additional","affiliation":[{"name":"Rare Diseases & Pediatric Medicine Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, 36312 Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9244-6513","authenticated-orcid":false,"given":"Marta","family":"Alves-Villar","sequence":"additional","affiliation":[{"name":"Rare Diseases & Pediatric Medicine Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, 36312 Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Fern\u00e1ndez-Pereira","sequence":"additional","affiliation":[{"name":"Rare Diseases & Pediatric Medicine Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, 36312 Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9391-4316","authenticated-orcid":false,"given":"Juli\u00e1n","family":"Fern\u00e1ndez-Mart\u00edn","sequence":"additional","affiliation":[{"name":"Rare Diseases & Pediatric Medicine Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, 36312 Vigo, Spain"},{"name":"Internal Medicine Department, SERGAS-Hospital Alvaro Cunqueiro, 36312 Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Rivera-Gallego","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, SERGAS-Hospital Alvaro Cunqueiro, 36312 Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Melc\u00f3n-Crespo","sequence":"additional","affiliation":[{"name":"Rare Diseases & Pediatric Medicine Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, 36312 Vigo, Spain"},{"name":"Pediatrics Department, SERGAS-Hospital Alvaro Cunqueiro, 36312 Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"San Mill\u00e1n-Tejado","sequence":"additional","affiliation":[{"name":"Rare Diseases & Pediatric Medicine Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, 36312 Vigo, Spain"},{"name":"Molecular Medicine PhD Program, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Ruz-Zafra","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hospital de la Serran\u00eda, 29400 Ronda, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remedios","family":"Garofano-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital de Torrecardenas, 04009 Almeria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"S\u00e1nchez-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Rare Disease Research Group, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), 03010 Alicante, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0032-0197","authenticated-orcid":false,"given":"Elena","family":"Garc\u00eda-Pay\u00e1","sequence":"additional","affiliation":[{"name":"Rare Disease Research Group, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), 03010 Alicante, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6544-533X","authenticated-orcid":false,"given":"Manuel","family":"L\u00f3pez-Mendoza","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Virgen del Roc\u00edo, 41013 Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Mart\u00edn-Su\u00e1rez","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hospital Universitario Juan Ram\u00f3n Jim\u00e9nez, 21005 Huelva, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1098-3376","authenticated-orcid":false,"given":"Saida","family":"Ortolano","sequence":"additional","affiliation":[{"name":"Rare Diseases & Pediatric Medicine Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, 36312 Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.molmed.2012.05.007","article-title":"Amino Acids and mTORC1: From Lysosomes to Disease","volume":"18","author":"Efeyan","year":"2012","journal-title":"Trends Mol. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-662-47453-2","article-title":"Innate and Adaptive Immune Response in Fabry Disease","volume":"Volume 22","author":"Zschocke","year":"2015","journal-title":"JIMD Reports"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ymgme.2013.02.003","article-title":"Fabry Disease Peripheral Blood Immune Cells Release Inflammatory Cytokines: Role of Globotriaosylceramide","volume":"109","author":"Francesco","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/eji.201545725","article-title":"Globotriaosylceramide Inhibits iNKT-Cell Activation in a CD1d-Dependent Manner","volume":"46","author":"Pereira","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1124\/pr.114.010090","article-title":"Toll-like Receptors in the Vascular System: Sensing the Dangers within","volume":"68","author":"Goulopoulou","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry Disease Revisited: Management and Treatment Recommendations for Adult Patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e010171","DOI":"10.1161\/CIRCIMAGING.119.010171","article-title":"Myocardial Edema, Myocyte Injury, and Disease Severity in Fabry Disease","volume":"13","author":"Augusto","year":"2020","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/ehjci\/jeaa101","article-title":"The Myocardial Phenotype of Fabry Disease Pre-Hypertrophy and Pre-Detectable Storage","volume":"22","author":"Augusto","year":"2021","journal-title":"Eur. Heart J.\u2014Cardiovasc. Imaging"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e008424","DOI":"10.1161\/CIRCIMAGING.118.008424","article-title":"Predictors of Clinical Evolution in Prehypertrophic Fabry Disease","volume":"12","author":"Camporeale","year":"2019","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Tebani, A., Mauhin, W., Abily-Donval, L., Lesueur, C., Berger, M.G., Nadjar, Y., Berger, J., Benveniste, O., Lamari, F., and Lafor\u00eat, P. (2020). A Proteomics-Based Analysis Reveals Predictive Biological Patterns in Fabry Disease. J. Clin. Med., 9.","DOI":"10.3390\/jcm9051325"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.trsl.2024.02.006","article-title":"Characterization of the Plasma Proteomic Profile of Fabry Disease: Potential Sex- and Clinical Phenotype-Specific Biomarkers","volume":"269","author":"Bravo","year":"2024","journal-title":"Transl. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2008.06.016","article-title":"Globotriaosylceramide Induces Oxidative Stress and Up-Regulates Cell Adhesion Molecule Expression in Fabry Disease Endothelial Cells","volume":"95","author":"Shen","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"100454","DOI":"10.1016\/j.ymgmr.2019.100454","article-title":"The Effect of Enzyme Replacement Therapy on Clinical Outcomes in Male Patients with Fabry Disease: A Systematic Literature Review by a European Panel of Experts","volume":"19","author":"Germain","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/eurheartj\/ehs166","article-title":"Left Ventricular Hypertrophy in Fabry Disease: A Practical Approach to Diagnosis","volume":"34","author":"Yousef","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1221.e1","DOI":"10.1016\/j.cjca.2015.10.033","article-title":"Evaluation of Proinflammatory Prognostic Biomarkers for Fabry Cardiomyopathy with Enzyme Replacement Therapy","volume":"32","author":"Chen","year":"2016","journal-title":"Can. J. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1395287","DOI":"10.3389\/fgene.2024.1395287","article-title":"Pegunigalsidase Alfa: A Novel, Pegylated Recombinant Alpha-Galactosidase Enzyme for the Treatment of Fabry Disease","volume":"15","author":"Germain","year":"2024","journal-title":"Front. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s Disease with the Pharmacologic Chaperone Migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Eng. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/cpt.790","article-title":"Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients with Fabry Disease on Enzyme Replacement","volume":"103","author":"Oder","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"106963","DOI":"10.1016\/j.ymgme.2022.11.002","article-title":"Venglustat, an Orally Administered Glucosylceramide Synthase Inhibitor: Assessment over 3 Years in Adult Males with Classic Fabry Disease in an Open-Label Phase 2 Study and Its Extension Study","volume":"138","author":"Deegan","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"440","DOI":"10.2174\/1570159X20666220601124117","article-title":"Fabry Disease: Current and Novel Therapeutic Strategies. A Narrative Review","volume":"21","author":"Palaiodimou","year":"2023","journal-title":"Curr. Neuropharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ymgme.2017.06.006","article-title":"Correlation of Lyso-Gb3 Levels in Dried Blood Spots and Sera from Patients with Classic and Later-Onset Fabry Disease","volume":"121","author":"Nowak","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"107585","DOI":"10.1016\/j.ymgme.2023.107585","article-title":"An Expert Consensus on the Recommendations for the Use of Biomarkers in Fabry Disease","volume":"139","author":"Burlina","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Monticelli, M., Liguori, L., Allocca, M., Bosso, A., Andreotti, G., Lukas, J., Monti, M.C., Morretta, E., Cubellis, M.V., and Hay Mele, B. (2022). Drug Repositioning for Fabry Disease: Acetylsalicylic Acid Potentiates the Stabilization of Lysosomal Alpha-Galactosidase by Pharmacological Chaperones. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23095105"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Monticelli, M., Hay Mele, B., Allocca, M., Liguori, L., Lukas, J., Monti, M.C., Morretta, E., Cubellis, M.V., and Andreotti, G. (2023). Curcumin Has Beneficial Effects on Lysosomal Alpha-Galactosidase: Potential Implications for the Cure of Fabry Disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021095"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.clinbiochem.2012.04.030","article-title":"Comparison between Alpha-Galactosidase A Activity in Blood Samples Collected on Filter Paper, Leukocytes and Plasma","volume":"45","author":"Daitx","year":"2012","journal-title":"Clin. Biochem."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"San Mill\u00e1n-Tejado, B., Navarro, C., Fern\u00e1ndez-Mart\u00edn, J., Rivera, A., Vi\u00e9itez, I., Teijeira, S., and Ortolano, S. (2023). Morphological Hallmarks of Classical Fabry Disease: An Ultrastructural Study in a Large Spanish Family. J. Clin. Med., 12.","DOI":"10.3390\/jcm12175689"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bbadis.2011.11.001","article-title":"Globotriaosylceramide Is Correlated with Oxidative Stress and Inflammation in Fabry Patients Treated with Enzyme Replacement Therapy","volume":"1822","author":"Biancini","year":"2012","journal-title":"Biochim. Biophys. Acta (BBA)\u2014Mol. Basis Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e2643","DOI":"10.6061\/clinics\/2021\/e2643","article-title":"Increased Serum Interleukin-6 and Tumor Necrosis Factor Alpha Levels in Fabry Disease: Correlation with Disease Burden","volume":"76","author":"Bento","year":"2021","journal-title":"Clinics"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1073\/pnas.0611315104","article-title":"Proteomic of specific treatment related alterations in Fabry Disease: A strategy to identify biological abnormalities","volume":"104","author":"Moore","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cyto.2012.12.011","article-title":"Vascular Endothelial Growth Factor (VEGF-a) in Fabry Disease: Association with Cutaneous and Systemic Manifestations with Vascular Involvement","volume":"61","author":"Zampetti","year":"2013","journal-title":"Cytokine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000521329","article-title":"Growth Differentiation Factor-15 and Syndecan-1 Are Potential Biomarkers of Cardiac and Renal Involvement in Classical Fabry Disease under Enzyme Replacement Therapy","volume":"47","author":"Biagini","year":"2022","journal-title":"Kidney Blood Press. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.acvd.2019.01.002","article-title":"Fabry Disease in Cardiology Practice: Literature Review and Expert Point of View","volume":"112","author":"Habib","year":"2019","journal-title":"Arch. Cardiovasc. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1177\/1076029617736382","article-title":"The Plasma Levels of ADAMTS-13, von Willebrand Factor, VWFpp, and Fibrin-Related Markers in Patients with Systemic Sclerosis Having Thrombosis","volume":"24","author":"Habe","year":"2018","journal-title":"Clin. Appl. Thromb.\/Hemostasis"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"542657","DOI":"10.3389\/fimmu.2020.00951","article-title":"Growth\/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint","volume":"11","author":"Wischhusen","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.arr.2018.07.004","article-title":"Towards Frailty Biomarkers: Candidates from Genes and Pathways Regulated in Aging and Age-Related Diseases","volume":"47","author":"Cardoso","year":"2018","journal-title":"Ageing Res. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1212\/01.wnl.0000247278.88077.09","article-title":"Myeloperoxidase predicts risk of vasculopathic events in hemizygous males with Fabry Disease","volume":"67","author":"Kanenski","year":"2006","journal-title":"Neurology"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Roy, A., Umar, H., Ochoa-Ferraro, A., Warfield, A., Lewis, N., Geberhiwot, T., and Steeds, R. (2021). Atherosclerosis in Fabry Disease\u2014A Contemporary Review. J. Clin. Med., 10.","DOI":"10.3390\/jcm10194422"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life Expectancy and Cause of Death in Males and Females with Fabry Disease: Findings from the Fabry Registry","volume":"11","author":"Waldek","year":"2009","journal-title":"Genet. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0009-8981(01)00478-8","article-title":"Fabry Disease: Enzymatic Diagnosis in Dried Blood Spots on Filter Paper","volume":"308","author":"Chamoles","year":"2001","journal-title":"Clin. Chim. Acta Int. J. Clin. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/j.ymgme.2016.11.262","article-title":"Plasma Lyso-Gb3: A Useful Biomarker for the Diagnosis and Treatment of Fabry Disease Heterozygotes","volume":"120","author":"Nowak","year":"2017","journal-title":"Mol. Genet. Metab."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/11\/6024\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:51:14Z","timestamp":1760107874000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/11\/6024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":40,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["ijms25116024"],"URL":"https:\/\/doi.org\/10.3390\/ijms25116024","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,30]]}}}